Author

Karen S. Anderson

Mayo Clinic in ArizonaORCID 0000-0002-3870-5730Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

DW NorthfeltiD· 2 shared Ahuva Odenheimer-Bergman· 1 shared Alexander R.A. AndersoniD· 1 shared Ann E. McCulloughiD· 1 shared Archana KiklaiD· 1 shared Barbara A. PockajiD· 1 shared Bhavika PateliD· 1 shared Bradon R. McDonaldiD· 1 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

DW NorthfeltORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BioengineeringbioRxivPreprintSep 17, 2026

Engineered mRNA nanostructures expand the design space of mRNA therapeutics through programmable protein expression and immune stimulation

Mark Knappenberger, Skylar J.W. Henry, Archana Kikla…·Petr Šulc

This paper introduces mRNA-OG, a programmable mRNA nanostructure that affects protein expression, delivery, and immune response through its architecture.

DOI 10.64898/2026.09.14.751315

humanmultiome

𝕏 PostBluesky

Cancer BiologyCancersPeer-reviewedJan 6, 2024

Testing Adaptive Therapy Protocols using Gemcitabine and Capecitabine on a Mouse Model of Endocrine-Resistant Breast Cancer

Sareh Seyedi, Ruthanne Teo, Luke Foster…·Carlo C. Maley

This study tests adaptive therapy protocols using gemcitabine and capecitabine on a mouse model of endocrine-resistant breast cancer, finding improved survival with adaptive strategies over high-dose combination therapy.

17 citationstop 5%

mouseexperimental assay

𝕏 PostBluesky

GenomicsScience Translational MedicinePeer-reviewedAug 7, 2019

Detection of residual disease after neoadjuvant therapy in breast cancer using personalized circulating tumor DNA analysis

Bradon R. McDonald, Tania Contente‐Cuomo, Stephen‐John Sammut…·Muhammed Murtaza

A personalized ctDNA test achieves high accuracy for residual disease detection after neoadjuvant therapy in breast cancer.

306 citationstop 1%

humanDNA methylation

𝕏 PostBluesky